FDA’s New ‘Super Office’ Attacks Pharmaceutical Quality Risks
This article was originally published in The Gold Sheet
Executive Summary
Launched this month, CDER’s OPQ ‘Super Office’ blends the agency’s CMC review programs for new and generic drugs together, and focuses them on significant risks like the difficulty of release-testing modified-release drugs.
You may also be interested in...
US FDA’s OPQ Reshapes For More Nimble Approach To Drug Quality Reviews
Reorganization in January expected to leave CDER’s nine-year-old pharmaceutical quality assessment organization more adaptable to public health emergencies, new pharmaceutical technologies and market dynamics, while further blending approaches to new and generic drug reviews.
FDA’s OPQ Chief Tells Generic Drug Makers Its Time To Up Their Quality Game
The head of US FDA’s drug quality office comments on quality-related topics at the GRx-Biosims meeting; sheds more light on facility rating system plan.
FDA Generics Research Forges Ahead After Agency’s Bupropion Mea Culpa
In an unusual essay in the New England Journal of Medicine, CDER Director Janet Woodcock acknowledges that “the conservative approach did not provide the right conclusion regarding therapeutic equivalence in a timely manner.”